Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Mar;47(1):89-95.
doi: 10.12865/CHSJ.47.01.14. Epub 2021 Mar 31.

VEGF Immunoexpression in Prostate Adenocarcinoma

Andrei Pănuş  1 , Cristiana Eugenia Simionescu  2 , Petru Octavian Drăgoescu  3 , Alex Emilian Stepan  2
Affiliations

VEGF Immunoexpression in Prostate Adenocarcinoma

Andrei Pănuş et al. Curr Health Sci J. 2021 Jan-Mar.

Abstract

Angiogenesis is a basic biomolecular mechanism for tumor progression, the vascular endothelial growth factor (VEGF) being one of the main enhancers of this complex process. In this study, we analyzed VEGF-A immunoexpression in 61 prostate adenocarcinomas (PAs), related to the prognostic parameters of the lesions. VEGF scores were higher in PAs that associated serum PSA values above 20ng/ml, in tumors with pure complex or mixed growth patterns, as well as in high-grade and advanced lesions. The results obtained indicate the involvement of VEGF in prostate angiogenesis and the usefulness of the maker for the identification of aggressive lesions.

Keywords: Gleason score; VEGF; prostate adenocarcinoma.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Figures

Figure 1
Figure 1
Prostate adenocarcinoma, VEGF immunostaining, x100. A. Growth pattern 3; B. Growth pattern 4; C. Mixed growth pattern 3 and 4; D. Mixed growth pattern 3 and 5
Figure 2
Figure 2
Distribution of cases depending on VEGF scores and PSA levels (A), growth pattern (B), Gleason score (C) and pT/tumor stage (D)
See this image and copyright information in PMC

References

    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89. - PMC - PubMed
    1. Siegel RL, Miller Kimberly DKD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. - PubMed
    1. Yang SC, Su LM, Carter HB, Chaussy C. Early diagnosis and treatment of cancer: Prostate Cancer. Philadelphia: Saunders Elsevier Publishing; 2009.
    1. Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110(11 Pt C):E794–808. - PubMed
    1. Rivera-Pérez J, Monter-Vera MDR, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncol Lett. 2018;15(1):1072–1078. - PMC - PubMed

LinkOut - more resources